Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients

Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients

Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma, has been shown to induce skin‐related adverse events in...

Full description

Bibliographic Details
Main Authors: Asahi Ito, Yui Suzuki, Ayako Masaki, Shinichiro Yoshida, Hitoshi Suzushima, Shigeki Takemoto, Atae Utsunomiya, Toshihiko Ishii, Masanori Hiura, Takeshi Takahashi, Satoshi Yurimoto, Hiroshi Inagaki, Akimichi Morita, Shinsuke Iida, Takashi Ishida
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Journal of Cutaneous Immunology and Allergy
Subjects:
CD8
FoxP3
mogamulizumab
Online Access:https://doi.org/10.1002/cia2.12070

Internet

https://doi.org/10.1002/cia2.12070

Similar Items